Hydroxychloroquine-Induced Skin Hyperpigmentation in Systemic Lupus Erythematosus Patient: A Case Report.

Medical archives (Sarajevo, Bosnia and Herzegovina) Pub Date : 2025-01-01 DOI:10.5455/medarh.2025.79.67-70

Anhar Zahrani, Shaimaa Salaam, Sahar Alsifri, Amjad Alghamdi, Mohammed Zamil

{"title":"Hydroxychloroquine-Induced Skin Hyperpigmentation in Systemic Lupus Erythematosus Patient: A Case Report.","authors":"Anhar Zahrani, Shaimaa Salaam, Sahar Alsifri, Amjad Alghamdi, Mohammed Zamil","doi":"10.5455/medarh.2025.79.67-70","DOIUrl":null,"url":null,"abstract":"Background: Hydroxychloroquine (HCQ) is an anti-malarial, antirheumatic disease-modifying medication. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus.Objective: This case report aims to describe the clinical features and outcome of hydroxychloroquine-induced skin hyperpigmentation in a patient with SLE.Case presentation: In this case report, we present a 32-year-old man with a history of Systemic lupus erythematosus who was treated with hydroxychloroquine. One year after treatment, the patient complained of diffused discoloration and melanonychia. Furthermore, punch biopsy from the involved sites showed pigment incontinence. To our knowledge, this is the only case reported with biopsy and photographic evidence from our geographical area.Conclusion: Hydroxychloroquine-induced pigmentation is not a rare adverse effect of HCQ. Biopsy revealed pigment incontinence. Additionally, our patient had no history of ecchymoses or anticoagulant therapy.","PeriodicalId":94135,"journal":{"name":"Medical archives (Sarajevo, Bosnia and Herzegovina)","volume":"79 1","pages":"67-70"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045584/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical archives (Sarajevo, Bosnia and Herzegovina)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/medarh.2025.79.67-70","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hydroxychloroquine (HCQ) is an anti-malarial, antirheumatic disease-modifying medication. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus.

Objective: This case report aims to describe the clinical features and outcome of hydroxychloroquine-induced skin hyperpigmentation in a patient with SLE.

Case presentation: In this case report, we present a 32-year-old man with a history of Systemic lupus erythematosus who was treated with hydroxychloroquine. One year after treatment, the patient complained of diffused discoloration and melanonychia. Furthermore, punch biopsy from the involved sites showed pigment incontinence. To our knowledge, this is the only case reported with biopsy and photographic evidence from our geographical area.

Conclusion: Hydroxychloroquine-induced pigmentation is not a rare adverse effect of HCQ. Biopsy revealed pigment incontinence. Additionally, our patient had no history of ecchymoses or anticoagulant therapy.

查看原文本刊更多论文

羟氯喹致系统性红斑狼疮患者皮肤色素沉着1例。

背景：羟氯喹（Hydroxychloroquine， HCQ）是一种抗疟疾、抗风湿病的药物。除了常见的不良反应外，HCQ还与皮肤表现有关，如色素沉着、白癜风和瘙痒。目的：本病例报告旨在描述羟基氯喹引起的SLE患者皮肤色素沉着的临床特征和结果。病例介绍：在这个病例报告中，我们提出了一个32岁的男性系统性红斑狼疮史谁是羟基氯喹治疗。治疗一年后，患者主诉弥漫性变色和黑甲癣。此外，累及部位的穿刺活检显示色素失禁。据我们所知，这是本地区唯一一例有活检和摄影证据的病例。结论：羟氯喹所致的色素沉着并不是HCQ罕见的不良反应。活检显示色素失禁。此外，我们的患者没有淤血史或抗凝治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical archives (Sarajevo, Bosnia and Herzegovina)

自引率

0.00%

发文量